WO2024098939A1 - Protéine de fusion bifonctionnelle et son utilisation - Google Patents

Protéine de fusion bifonctionnelle et son utilisation Download PDF

Info

Publication number
WO2024098939A1
WO2024098939A1 PCT/CN2023/117865 CN2023117865W WO2024098939A1 WO 2024098939 A1 WO2024098939 A1 WO 2024098939A1 CN 2023117865 W CN2023117865 W CN 2023117865W WO 2024098939 A1 WO2024098939 A1 WO 2024098939A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
fusion protein
seq
cancer
acid sequence
Prior art date
Application number
PCT/CN2023/117865
Other languages
English (en)
Chinese (zh)
Inventor
姜彦静
王伟欢
周景云
田新生
马荣
张小锐
刘向蒙
张筠
李自强
Original Assignee
北京伟德杰生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京伟德杰生物科技有限公司 filed Critical 北京伟德杰生物科技有限公司
Publication of WO2024098939A1 publication Critical patent/WO2024098939A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Definitions

  • the present invention relates to the field of fusion proteins, and more specifically to a bifunctional fusion protein targeting IL-6R and CD47 and applications thereof.
  • Interleukin-6 is a multifunctional cytokine discovered in 1980 and produced by various types of cells such as T cells, B cells, monocytes, fibroblasts, osteoblasts, keratinocytes, endothelial cells, mesangial cells and some tumor cells. It contains four ⁇ -helical domains with a motif of four cysteine residues necessary for the tertiary structure.
  • Human IL-6 is a 26-kDa glycoprotein whose gene is present on chromosome 7. IL-6 mainly acts by binding to the receptor cell IL-6R and then transmitting downstream signal molecules.
  • interleukin-6 (IL-6) binding receptors There are two types of interleukin-6 (IL-6) binding receptors, one is the specific receptor IL-6R (80kDa type I transmembrane protein), and the other is gp130, which is a common receptor subunit for all members of the IL-6 family of cytokines. gp130 can be expressed in all cells, but the expression of interleukin-6 receptor (IL-6R) is more restricted and is mainly found in hepatocytes, neutrophils, monocytes and CD4+T cells. Dimerization of the interleukin 6 receptor gp130 leads to the initiation of cellular events including activation of the JAK-STAT3 pathway and ras-mediated MAP kinase signaling.
  • IL-6R interleukin-6 receptor
  • IL-6R is highly expressed in a variety of human tumor cells, including promyelocytic leukemia, astrocytoma, glioblastoma, multiple myeloma, prostate cancer, gastric cancer, and liver cancer cells. Therefore, targeting IL-6 or IL-6R, blocking the binding of IL-6 to IL-6R, and thus inhibiting IL-6 pathway signal transduction, this IL-6 pathway inhibitor has opened a new journey as a potential treatment for a variety of diseases.
  • Tocilizumab (TCZ) is the first humanized monoclonal antibody targeting interleukin-6 receptor (IL-6R). It is an IgG1 antibody obtained by humanizing the mouse antibody PM1. Tocilizumab can be used as a therapeutic agent for IL-6-related diseases and has been sold under the trade names Actemra and RoActemra.
  • the cell surface protein CD47 is expressed or overexpressed on many tumor types, including acute myeloid leukemia, multiple subtypes of B-cell non-Hodgkin lymphoma, and many human solid tumor cells.
  • CD47 is widely considered to be a "don't eat me” signal that helps maintain immune tolerance of non-malignant cells under physiological conditions, but this molecule can help cancer cells survive in different cancer types.
  • SIRP ⁇ signal regulatory protein alpha
  • Therapies that inhibit CD47 signaling in cancer cells may promote phagocytosis of tumor cells by macrophages, thereby limiting tumor growth. This provides a viable immune target for anti-tumor therapy.
  • anti-CD47 antibodies also help to enhance effective anti-tumor T cell responses in immune-tolerant mice. Therefore, anti-CD47 antibodies are a new class of immune checkpoint inhibitors that regulate both the innate and adaptive immune systems.
  • CD47 drugs As a new target, the development of CD47 drugs has not been smooth, and has been stagnant due to severe adverse blood reactions. This is mainly because normal cells such as red blood cells also express CD47. Any CD47-targeted drug that can bind to red blood cells may cause red blood cell destruction through two mechanisms alone or in combination, leading to severe blood toxicity, anemia, thrombocytopenia, etc. Side effects, and the efficacy is affected by the "antigen sinking effect".
  • the present invention provides a new fusion protein, which can simultaneously activate innate and adaptive immune responses to inhibit tumor immune escape and achieve a synergistic anti-tumor effect by blocking the IL-6R signaling pathway.
  • One aspect of the present invention provides a bifunctional fusion protein, which includes: a first domain that specifically recognizes interleukin-6 receptor (IL-6R), and a second domain that specifically binds to cell surface protein CD47.
  • IL-6R interleukin-6 receptor
  • the first domain is an antibody or a functional fragment thereof that specifically recognizes IL-6R.
  • the first domain may include an immunoglobulin (Ig) domain of an IL-6R antibody.
  • the second domain is a signal regulatory protein alpha peptide (SIRP ⁇ peptide) that specifically binds to CD47 or a functional fragment thereof.
  • SIRP ⁇ peptide signal regulatory protein alpha peptide
  • the first domain comprises an antibody Fab fragment, Fab' fragment, F(ab') 2 fragment, Fv fragment, scFv fragment, nanobody, heavy chain variable region (VH) fragment, or light chain variable region (VL) fragment that specifically binds to IL-6R.
  • the SIRP ⁇ peptide is selected from SIRP ⁇ V1, SIRP ⁇ V2, SIRP ⁇ V8, or a peptide having 1, 2 or 3 amino acids inserted, substituted or deleted compared to the amino acid sequence of SIRP ⁇ V1, SIRP ⁇ V2, SIRP ⁇ V8.
  • the first domain and the second domain are directly connected or connected through a linker.
  • the linker has an amino acid sequence as shown in the general formula (G n S) m , where n and m are integers of 1-10, respectively; more preferably, n is an integer of 1-4, m is an integer of 1-3, or an amino acid sequence having 1, 2 or 3 amino acids inserted, substituted or deleted compared to the amino acid sequence shown in the general formula (G n S) m .
  • the linker comprises at least 6 amino acids.
  • the bifunctional fusion protein comprises a first domain and a second domain connected in any manner. In some embodiments, the bifunctional fusion protein comprises a first domain-a second domain from the N-terminus to the C-terminus.
  • the first domain comprises: a heavy chain having an amino acid sequence as shown in SEQ ID NO:1 or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with SEQ ID NO:1; and a light chain having an amino acid sequence as shown in SEQ ID NO:2 or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with SEQ ID NO:2.
  • one or more of the amino acids 236, 237, 239, 332, and 333 corresponding to SEQ ID NO:1 are substituted.
  • the amino acid at position 236 corresponding to SEQ ID NO:1 is not leucine, and/or the amino acid at position 237 is not leucine, and/or the amino acid at position 239 is not glycine, and/or the amino acid at position 332 is not alanine, and/or the amino acid at position 333 is not proline.
  • the amino acid at position 236 corresponding to SEQ ID NO:1 is substituted with alanine, and/or the amino acid at position 237 is substituted with glutamic acid, and/or the amino acid at position 239 is substituted with alanine, and/or the amino acid at position 332 is substituted with serine, and/or the amino acid at position 333 is substituted with serine.
  • the first domain comprises an amino acid sequence as shown in SEQ ID NO:4 or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with SEQ ID NO:4.
  • the second domain comprises an amino acid sequence as set forth in SEQ ID NO:5 or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity to SEQ ID NO:5.
  • the second domain comprises an amino acid sequence as set forth in SEQ ID NO:6 or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity to SEQ ID NO:6.
  • the second domain comprises an amino acid sequence as set forth in SEQ ID NO:7 or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity to SEQ ID NO:7.
  • the second domain comprises an amino acid sequence as set forth in SEQ ID NO:8 or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity to SEQ ID NO:8.
  • the bifunctional fusion protein comprises an amino acid sequence as set forth in SEQ ID NO:9, or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the amino acid sequence as set forth in SEQ ID NO:9.
  • the bifunctional fusion protein comprises an amino acid sequence as set forth in SEQ ID NO:10, or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the amino acid sequence as set forth in SEQ ID NO:10.
  • the bifunctional fusion protein comprises an amino acid sequence as set forth in SEQ ID NO:11, or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the amino acid sequence as set forth in SEQ ID NO:11.
  • the bifunctional fusion protein comprises an amino acid sequence as set forth in SEQ ID NO: 12, or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the amino acid sequence as set forth in SEQ ID NO: 12.
  • the bifunctional fusion protein comprises an amino acid sequence as set forth in SEQ ID NO: 13, or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the amino acid sequence as set forth in SEQ ID NO: 13.
  • the bifunctional fusion protein also includes an amino acid sequence as shown in SEQ ID NO:2, or an amino acid sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the amino acid sequence shown in SEQ ID NO:2.
  • a monoclonal antibody against interleukin-6 receptor (IL-6R) (206mab, which has SEQ ID NO: 1
  • the amino acid sequence shown in SEQ ID NO:4 is based on the original drug tocilizumab (TCZ), and 5 mutations were made in the variable region, namely Phe51, Met57 and Ile103 on the heavy chain; Gln89 and Arg93 on the light chain, which increased the affinity with IL6R by hundreds of times and the biological activity by about 30 times.
  • the bifunctional fusion protein composed of IL-6R monoclonal antibody and natural SIRP ⁇ peptide can inhibit tumor immune escape by activating innate and acquired immune responses at the same time, and achieve synergistic anti-tumor effects by blocking the IL-6R signaling pathway.
  • the SIRP ⁇ peptide is selected from SIRP ⁇ V2D1.
  • the SIRP ⁇ V2 variant accounts for the largest proportion in the East Asian population (41.3%) and Domain 1 of the natural variant V2 can bind to tumor cell CD47 with high affinity but not to red blood cell CD47, and is therefore safer.
  • Another aspect of the present invention provides an isolated nucleic acid molecule encoding the bifunctional fusion protein of the present invention.
  • the isolated nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:14, or a nucleotide sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the nucleotide sequence as set forth in SEQ ID NO:14. In some embodiments, the isolated nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:15, or a nucleotide sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the nucleotide sequence as set forth in SEQ ID NO:15.
  • the isolated nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:16, or a nucleotide sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the nucleotide sequence as set forth in SEQ ID NO:16. In some embodiments, the isolated nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO: 17, or a nucleotide sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity to the nucleotide sequence as set forth in SEQ ID NO: 17.
  • the isolated nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO: 18, or a nucleotide sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity to the nucleotide sequence as set forth in SEQ ID NO: 18.
  • the isolated nucleic acid molecule comprises a nucleotide sequence as shown in SEQ ID NO:3, or a nucleotide sequence having at least about 85%, 90%, 95%, 98%, 99% or 100% sequence identity with the nucleotide sequence shown in SEQ ID NO:3.
  • the fusion protein of the present invention forms a dimer. In some embodiments, the fusion protein of the present invention forms a homodimer. In some embodiments, the fusion protein of the present invention forms a heterodimer.
  • nucleic acid delivery vector comprising the isolated nucleic acid molecule of the present invention.
  • the nucleic acid delivery vector comprises a nucleic acid delivery vector derived from adenovirus, adeno-associated virus, lentivirus or other acceptable nucleic acid delivery vectors.
  • Another aspect of the present invention provides a host cell comprising the isolated nucleic acid molecule of the present invention.
  • the pharmaceutical composition comprises the bifunctional fusion protein of the present invention and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition comprises the isolated nucleic acid molecule of the present invention and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition comprises the nucleic acid delivery vector of the present invention and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is in the form of tablets, powders, granules, pills, injections, suspensions, powders, emulsions, aerosols, gels, eye drops, sustained release agents or sustained release implants.
  • the pharmaceutical composition can be formulated into an injectable formulation.
  • the formulation is suitable for intravitreal injection, subcutaneous, intradermal, intramuscular, intravenous, intrathecal or intraspinal administration.
  • the medicine box includes a pharmaceutical composition of the present invention, and the pharmaceutical composition is packaged in a container.
  • the container is a glass ampoule, a glass bottle, a plastic ampoule, a plastic bottle, a plastic bag or a prefilled syringe.
  • the present invention relates to a pharmaceutical unit dosage form suitable for parenteral administration to humans, the pharmaceutical unit dosage form is included in a pharmaceutical composition as described herein in a suitable container.
  • the suitable container is a prefilled syringe.
  • the prefilled syringe includes an injection needle.
  • Another aspect of the present invention provides a method for treating or preventing diseases associated with IL-6 and/or CD47.
  • the method comprises administering to a subject a therapeutically effective amount of the bifunctional fusion protein of the present invention, the isolated nucleic acid molecule of the present invention, or the nucleic acid delivery vector of the present invention.
  • the disease is selected from cancer-related diseases. In some embodiments, the disease is selected from myelodysplastic syndrome. In some embodiments, the disease is selected from promyelocytic leukemia, acute myeloid leukemia, lymphoid leukemia, non-Hodgkin's lymphoma, melanoma, leiomyosarcoma, astrocytoma, glioblastoma, multiple myeloma, prostate cancer, gastric cancer, liver cancer, breast cancer, kidney cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, colorectal cancer, non-small cell lung cancer, bladder cancer, pancreatic cancer, liver cancer and cervical cancer.
  • the present invention provides a bifunctional fusion protein that can specifically bind to IL-6R and CD47.
  • a bifunctional fusion protein that can specifically bind to IL-6R and CD47.
  • the monoclonal cell line of the present invention can secrete and express the bifunctional fusion protein of IL-6R antibody and SIRP ⁇ .
  • the bifunctional fusion protein of the present invention can reduce the affinity with the CD47 domain on the surface of red blood cells, reduce the binding of antibodies to cells such as red blood cells, thereby increasing safety and improving the treatment window.
  • the IL-6R antibody can specifically recognize IL-6R on the surface of specific tumor cells, allowing the bifunctional fusion protein to aggregate on the target cells and inhibit tumor immune escape by activating innate and acquired immune responses through SIRP ⁇ .
  • the term “about” refers to a range of ⁇ 20% of the value that follows. In some embodiments, the term “about” refers to a range of ⁇ 10% of the value that follows. In some embodiments, the term “about” refers to a range of ⁇ 5% of the value that follows.
  • fusion protein refers to the use of genetic expression of polynucleotides encoding proteins or protein synthesis methods to connect two or more proteins or fragments thereof colinearly through their respective peptide backbones.
  • the proteins or fragments thereof are from different sources.
  • SPR surface plasmon resonance
  • the term "specific recognition” or “specific binding” means that the fusion protein has recognition and binding selectivity for a receptor or ligand, and can be distinguished from unwanted or non-specific binding.
  • the degree of binding of the bifunctional fusion protein of the present invention to unrelated proteins is less than about 10% of the degree of binding to IL-6R and CD47, for example, as measured by SPR.
  • the bifunctional fusion protein provided by the present invention binds to IL-6R and CD47 with a KD of 10-7 M or less, for example, 10-10 M to 10-11 M.
  • substitution refers to the replacement of at least one amino acid residue in an amino acid sequence by another different “replacement” amino acid residue.
  • insertion refers to the incorporation of at least one additional amino acid into an amino acid sequence.
  • inserts typically consist of the insertion of 1 or 2 amino acid residues
  • larger “peptide inserts” can also be prepared, for example, inserting about 3 to 5 or even up to about 10, 15 or 20 amino acid residues.
  • the inserted residues can be naturally occurring or non-naturally occurring.
  • deletion as used herein for amino acids refers to the removal of at least one amino acid residue from an amino acid sequence.
  • Fusion protein of the present disclosure or its fragment can comprise conservative amino acid substitution at one or more amino acid residues, for example, at essential or non-essential amino acid residues.
  • Consservative amino acid substitution is that amino acid residues are replaced by amino acid residues with similar side chains.
  • Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), ⁇ -branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
  • basic side chains e.g., lysine, arginine, histidine
  • acidic side chains e.g., aspart
  • the essential or non-essential amino acid residues in the fusion protein or connexon are preferably replaced with another amino acid residue from the same side chain family.
  • the amino acid segment can be replaced with a segment having a similar structure and a different order and/or composition of the side chain family members.
  • mutations can be introduced randomly along all or a portion of a coding sequence, such as by saturation mutagenesis, and the resulting mutants can be incorporated into fusion proteins of the invention and screened for the ability of these polypeptides to bind to a desired target.
  • antibody as used herein includes intact antibodies and any antigen-binding fragment (i.e., "antigen-binding portion,””antigen-bindingpolypeptide,” or “immunobinder”), or single chains thereof.
  • An “antibody” is a glycoprotein comprising A glycoprotein of at least two heavy chains (H) and two light chains (L) connected, or an antigen binding portion thereof.
  • Each heavy chain includes a heavy chain variable (VH) region and a heavy chain constant region (CH).
  • Each light chain includes a light chain variable (VL) region and a light chain constant region (CL).
  • the VH region and the VL region each contain three regions with highly variable amino acid composition and arrangement order, called hypervariable regions or complementarity determining regions (CDR), CDR1, CDR2 and CDR3.
  • CDR complementarity determining regions
  • the amino acid composition and arrangement order of the regions in the VH region and the VL region except the CDR region are relatively conservative, called the framework region (FR).
  • FR framework region
  • VH or VL each has four framework regions, represented by FR1, FR2, FR3 and FR4, respectively.
  • immunoglobulins There are five major classes of immunoglobulins, IgA, IgD, IgE, IgG, and IgM, and these major classes can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.
  • the heavy chain constant domains corresponding to different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • the CL lengths of different types ( ⁇ or ⁇ ) of immunoglobulins are basically the same, but the CH lengths of different classes of immunoglobulins are different, for example, IgG, IgA, and IgD include CH1, CH2, and CH3, while IgM and IgE include CH1, CH2, CH3, and CH4.
  • the hinge region is located between CH1 and CH2, is rich in proline, and is easy to stretch and bend, thereby changing the distance between the antigen binding sites, which is conducive to the antibody binding to antigen epitopes located at different positions.
  • the hinge region is easily hydrolyzed by papain, pepsin, etc., producing different hydrolysis fragments.
  • the Fab segment is an antigen binding fragment (Fab), which consists of a complete light chain and the VH and CH1 domains of the heavy chain.
  • homodimer refers to a fusion protein of the present invention, including two identical fusion proteins of the present invention.
  • heterodimer refers to a fusion protein of the present invention, including two different fusion proteins of the present invention.
  • mammals include but are not limited to domesticated animals (such as cows, horses, dogs, sheep, goats, cats and dogs), primates (such as humans and monkeys) and rodents (such as rabbits, mice and rats).
  • domesticated animals such as cows, horses, dogs, sheep, goats, cats and dogs
  • primates such as humans and monkeys
  • rodents such as rabbits, mice and rats
  • Numerical ranges used herein should be understood to include all numbers within the range. For example, a range of 1 to 20 should be understood to include any number, combination of numbers, or subrange from the following group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
  • linker refers to a (peptide) linker of natural and/or synthetic origin, consisting of linear amino acids.
  • the domains in the bifunctional fusion protein of the present invention can be connected by linkers, wherein each linker is fused to at least two polypeptides or domains and/or connected in other ways (e.g., via a peptide bond).
  • the amino acid sequences of all linkers present in the bifunctional fusion protein of the present invention are identical.
  • the amino acid sequences of at least two linkers present in the bifunctional fusion protein of the present invention are different.
  • the linker should have a length suitable for connecting two or more monomer domains in this manner, and the linker can ensure that the different domains to which it is connected are correctly folded and appropriately presented, thereby exerting their biologically active functions.
  • the linker has a flexible conformation. Suitable flexible linkers include, for example, having glycine, glutamine and/or serine residues.
  • the linker The amino acid residues can be arranged in small repeating units of up to 5 amino acids.
  • Percent (%) sequence identity refers to the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in the reference amino acid sequence, after alignment of the sequences and (as required) introduction of gaps to obtain maximum percentage sequence identity, but without considering any conservative substitutions as part of the sequence identity.
  • alignment can be performed in various ways within the scope of the art, such as using BLAST, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required for achieving maximum alignment over the full length of the compared sequences.
  • pharmaceutically acceptable carrier refers to a component of a pharmaceutical preparation other than an active ingredient that is non-toxic to a subject.
  • Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.
  • the term "treat” refers to alleviating and/or ameliorating a disorder and/or a disease or symptom associated therewith, as well as preventing the deterioration of the symptoms of a disorder.
  • the desired therapeutic effect includes, but is not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the progression of the disease, improving or alleviating symptoms, alleviating or improving prognosis.
  • treating a disease or symptom does not require completely eliminating the disease or the symptoms associated therewith.
  • the term "effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or preventive effect.
  • FIG1 shows a schematic diagram of the structure of the bifunctional fusion protein constructed in the present invention.
  • FIG2 shows the reducing SDS-PAGE results of the transiently expressed bifunctional fusion protein of the present invention, wherein lane 1 is PLS2124 (206mab-H-SIRP ⁇ V1D1) 1 ⁇ g, lane 2 is PLS2124 (206mab-H-SIRP ⁇ V1D1) 2 ⁇ g, lane 3 is Ladder, lane 4 is PLS2125 (206mab-H-SIRP ⁇ V2D1) 1 ⁇ g, lane 5 is PLS2125 (206 lane 6 is PLS2126 (206mab-H-SIRP ⁇ V1D1sg) 1 ⁇ g, lane 7 is PLS2126 (206mab-H-SIRP ⁇ V1D1sg) 2 ⁇ g, lane 8 is PLS2127 (206mab-H-SIRP ⁇ V2D1lm) 1 ⁇ g, and lane 9 is PLS2127 (206mab-H-SIRP ⁇ V2
  • FIG3 shows the non-reducing SDS-PAGE results of the transiently expressed bifunctional fusion protein of the present invention, wherein lane 1 is PLS2124 (206mab-H-SIRP ⁇ V1D1) 1 ⁇ g, lane 2 is PLS2124 (206mab-H-SIRP ⁇ V1D1) 2 ⁇ g, lane 3 is Ladder, lane 4 is PLS2125 (206mab-H-SIRP ⁇ V2D1) 1 ⁇ g, lane 5 is PLS2125 (20 Lane 6 is PLS2126 (206mab-H-SIRP ⁇ V1D1sg) 1 ⁇ g, lane 7 is PLS2126 (206mab-H-SIRP ⁇ V1D1sg) 2 ⁇ g, lane 8 is PLS2127 (206mab-H-SIRP ⁇ V2D1lm) 1 ⁇ g, and lane 9 is PLS2127 (206mab-H-SIRP ⁇ V2D
  • FIG4 shows the reporter gene assay results of PLS2125 of the present invention blocking the binding of IL6 to cell surface IL6R.
  • FIG5 shows the HTRF detection result of PLS2125 of the present invention blocking the binding between CD47 and SIRP ⁇ .
  • FIG6 shows the SDS-PAGE results of the protein expressed by the high-expression cell line PLT300-8#8C4 of the present invention, wherein M is a marker, NR is a non-reducing SDS-PAGE result, and R is a reducing SDS-PAGE result.
  • FIG. 7 shows the SEC-HPLC detection results of the protein expressed by the high-expressing cell line PLT300-8#8C4 of the present invention.
  • FIG. 8 shows the cIEF identification results of the protein expressed by the high-expressing cell line PLT300-8#8C4 of the present invention.
  • FIG. 9 shows the SEC-HPLC detection results of the protein expressed by the high-expressing cell line PLT300-8#8C4 of the present invention after repeated freezing and thawing.
  • FIG. 10 shows the SDS-PAGE results of the protein expression samples of the high-expressing cell line PLT300-8#8C4 of the present invention after repeated freezing and thawing.
  • FIG. 11 shows the SEC-HPLC detection results of the protein expressed by the high-expressing cell line PLT300-8#8C4 of the present invention at 40° C. accelerated sample.
  • FIG. 12 shows the detection results of the bifunctional fusion protein of the present invention binding to human red blood cells.
  • FIG. 13 shows the results of detecting the macrophage phagocytic activity of the bifunctional fusion protein of the present invention.
  • the bifunctional fusion protein IL-6R antibody and SIRP ⁇ peptide of the present invention has a structure as shown in Figure 1, wherein the IL-6R antibody is 206mab and its mutant 206mab-mut, 206mab is a genetically modified drug of the interleukin-6 receptor monoclonal antibody drug tocilizumab (TCZ), and is a mutant modified on the basis of tocilizumab with multiple times increased affinity.
  • SIRP ⁇ peptide is a natural variant, which can be the three variants of SIRP ⁇ V1, SIRP ⁇ V2, and SIRP ⁇ V8 contained in SIRP ⁇ peptide, and amino acids are substituted, deleted, and/or one or more amino acids are added on the basis thereof.
  • a connecting peptide is provided between the IL-6R antibody and the SIRP ⁇ peptide, and the general formula of the connecting peptide is ( GnS ) m , n and m are integers of 1 to 10, respectively, preferably, n is an integer of 1 to 4, and m is an integer of 1 to 3.
  • the present invention first constructs 206mab-L and fusion gene vectors PLS2124 (206mab-H-SIRP ⁇ V1D1), PLS2125 (206mab-H-SIRP ⁇ V2D1), PLS2126 (206mab-H-SIRP ⁇ V1D1sg), and PLS2127 (206mab-H-SIRP ⁇ V2D1im); PLS2124, PLS2125, PLS2126, and PLS2127 are co-transfected with 206mab-L for HEK293 transient expression; a bifunctional fusion protein is obtained by conventional purification; after the obtained protein is correctly identified by electrophoresis, affinity detection is performed on the target protein obtained by transient expression.
  • the truncated sequence of natural SIRP ⁇ V2D1 was selected, and AEASS amino acid mutations (L236A, L237E, G239A, A 332S, P333S), the ADCC effect was removed, and the mutant 206mab-H and SIRP ⁇ V2D1 were connected with a linker (G n S) m , and inserted into the same vector with 206mab-L to construct the plasmid PLT300 (206mab-mut-SIRP ⁇ V2D1) for stable transfection of CHO cells.
  • AEASS amino acid mutations L236A, L237E, G239A, A 332S, P333S
  • the PLT300 plasmid was electroporated into CHO cells to obtain a CHO monoclonal cell line that stably and efficiently expresses human recombinant proteins.
  • the drugability analysis of the antibodies expressed by the screened monoclonal cell lines showed that the protein had strong stability and good drugability.
  • the structure of the bifunctional fusion protein of IL-6R antibody and SIRP ⁇ peptide is shown in Figure 1, wherein the IL-6R antibody is 206mab (its amino acid sequence and nucleotide sequence are shown below) and its mutant 206mab-mut (its amino acid sequence and nucleotide sequence are shown below), 206mab is a genetically modified drug of the interleukin-6 receptor monoclonal antibody drug tocilizumab (TCZ), which is based on tocilizumab and has 5 mutations in the variable region: Phe51, Met57 and Ile103 on the heavy chain, Gln89 and Arg93 on the light chain, which increases the affinity of 206mab to IL-6R by hundreds of times and the biological activity by about 30 times.
  • TCZ interleukin-6 receptor monoclonal antibody drug tocilizumab
  • the SIRP ⁇ peptide is a natural variant, which may be the three variants of SIRP ⁇ peptide, SIRP ⁇ V1, SIRP ⁇ V2, and SIRP ⁇ V8, and amino acids are substituted, deleted, and/or one or more amino acids are added thereto.
  • a linker is provided between the IL-6R antibody and the SIRP ⁇ peptide (the amino acid sequence and nucleotide sequence of which are shown below), and the linker sequence is shown underlined in the corresponding sequence.
  • 206mab-L and fusion gene vectors PLS2124 (206mab-H-SIRP ⁇ V1D1, the specific sequence is shown below), PLS2125 (206mab-H-SIRP ⁇ V2D1, the specific sequence is shown below), PLS2126 (206mab-H-SIRP ⁇ V1D1sg, the specific sequence is shown below), and PLS2127 (206mab-H-SIRP ⁇ V2D1im, the specific sequence is shown below) were first constructed. PLS2124, PLS2125, PLS2126, and PLS2127 were transiently expressed by co-transfection with 206mab-L in HEK293, and the bifunctional fusion protein was obtained by conventional purification.
  • the truncated sequence of natural SIRP ⁇ V2D1 was further selected, and AEASS amino acid mutations (L236A, L237E, G239A, A332S, P333S) were performed on 206mab-H to obtain the 206mab mutant 206mab-mut that eliminated the ADCC effect.
  • the mutant 206mab-H and SIRP ⁇ V2D1 were connected with ( GnS ) m and inserted into the same vector as 206mab-L to construct the plasmid PLT300 (206mab-mut-SIRP ⁇ V2D1, the specific sequence is shown in Table 1) for stable transfection of CHO cells.
  • This example uses bio-layer interferometry (BLI) to determine affinity.
  • the transiently expressed dual-function fusion protein was diluted to 20nM and adsorbed onto the ProA probe at a speed of 400rpm/min.
  • CD47 was diluted from 400nM to 5 concentration gradients.
  • the program was set so that the diluted CD47 was bound to the ProA probe attached with the dual-function fusion protein within a fixed time.
  • the probe of the complex was transferred to the Q buffer without the analyte to dissociate the bound analyte.
  • the data was fitted using the built-in software of the gator instrument to obtain the KD value. The results are shown in Table 2.
  • the biological activity of 206mab was detected by 293-IL6Res cell/reporter gene method. Rinse the cells with preheated sterile PBS for 3-5 seconds, remove the PBS, add trypsin for digestion, and add basal medium to terminate digestion when the cells fall off. Centrifuge and discard the supernatant, resuspend and count, adjust the cell density to 5 ⁇ 10 5 cells/ml, and add 80 ⁇ l/well to the corresponding wells. Dilute IL6 to 50ng/ml with basal medium, add 10 ⁇ l/well to the sample well and positive control well, and add 10 ⁇ l/well basal medium to the negative well.
  • the data was processed using a four-parameter fitting curve, with the logarithm of the concentration of the standard or test sample as the horizontal axis and the RLU value as the vertical axis to calculate the IC50 value of the test sample.
  • the results are shown in Figure 4.
  • the IC50 value of 206mab is 0.1479
  • the IC50 value of PLS2125 (206mab-H-SIRP ⁇ V2D1) is 0.03919.
  • CHO-K1 cells One day before transfection, adjust the density of CHO-K1 cells to 0.5 ⁇ 10 6 cells/mL. On the day of transfection, prepare linearized, high-concentration endotoxin-free plasmids, measure the density and viability of CHO-K1 cells, and ensure that the cell viability is greater than 97%. After washing CHO-K1 cells twice with CD CHO medium, take 700 ⁇ L of cell suspension, add 40 ⁇ g of plasmid, mix well, transfer to a 4mm electrode cup, and put it into the electroporator. Set the electroporation parameters to 300V, 1000 ⁇ F, electroporate once, transfer the electroporated cell suspension to preheated fresh CD CHO medium, and incubate at 37°C for 20min.
  • the incubated cell suspension is evenly inoculated in a 96-well plate. After 24h of transfection, pressurize and add CD CHO medium containing methionine iminosulfone (MSX). The final screening pressure is 25-50 ⁇ M MSX, 5% CO 2 , and static culture at 37°C. After the single clones in the 96-well plate grow to a suitable size, start to select single clones and transfer all clones to a new 96-well plate and culture them at 5% CO 2 and 37°C.
  • MSX methionine iminosulfone
  • the purified protein was identified by reducing and non-reducing SDS-PAGE electrophoresis (results shown in Figure 6) and SEC-HPLC (results shown in Figure 7).
  • the cell line 8#8C4 with good stability and high expression level was selected for drugability analysis.
  • the drugability analysis of the protein expressed and purified by the screened PLT300-8#8C4 cell line was performed.
  • the protein was divided into 6 tubes, 1 ml/tube. One of them was not treated and used as a zero-point control. At the same time, it was identified by cIEF.
  • the results are shown in Figure 8.
  • the other two tubes were taken and frozen and thawed 3 and 5 times respectively, and then SEC-HPLC was tested.
  • the results are shown in Table 4 and Figure 9; the reduced SDS-PAGE (R) and non-reduced SDS-PAGE (NR) were tested, and the results are shown in Figure 10.
  • the data showed that the purity of the protein was consistent before and after freezing and thawing, and it was relatively stable.
  • Fresh healthy human blood was mixed with an equal volume of PBS, centrifuged at 300g for 5min to obtain a cell mass, and then washed with PBS for 3-5 times to obtain red blood cells.
  • Resuspended with FACS buffer PBS + 5% BSA
  • the cell density was adjusted to 2 ⁇ 10 6 /ml
  • 10 ⁇ g/ml 206mab or 10 ⁇ g/ml PLT300 were added, incubated at 4°C for 1 hour, and then washed twice with FACS buffer (PBS + 2% FBS), and then the antibody Goat Anti-Human IgG (H+L) was added, incubated on ice in the dark for 30min, and finally washed twice with FACS buffer and resuspended.
  • PBMCs were isolated from fresh human blood, and CD14+ monocytes were sorted using CD14 magnetic beads. Differentiation was induced in macrophage differentiation medium (1640+10% FBS+50ng/ml GM-CSF) for 7 days; then treated with macrophage differentiation medium (1640+10% FBS+50ng/ml IFNr) for 2 days. Macrophages were scraped and plated in 6-well plates, with 1 ⁇ 10 6 cells per well. On the day of the experiment, Raji cells were labeled with 0.5 ⁇ M CFSE for 15 minutes at room temperature.
  • CFSE-Raji was incubated with macrophages at 3 times the number of cells, and PLT300 (20 ⁇ g/ml), h5F9 (20 ⁇ g/ml) and PBS solution were added at the same time. After phagocytosis reaction for 4 hours, the suspended cells were removed and washed twice with PBS. Cells were scraped, centrifuged and resuspended in PBS, and antibody Fc blocking agent was added to eliminate nonspecific binding. Then CD14-APC antibody was added to label macrophages and reacted at 4°C for 30 minutes. After fluorescent antibody staining, the cells were washed twice with PBS and analyzed using a flow cytometer. Macrophages were identified by the APC-labeled positive cell population, and the percentage of CFSE+ positive cells was analyzed based on this subpopulation, which was the phagocytic rate. The results are shown in Figure 13.
  • mice Human PBMCs were injected into NSG severely immunodeficient mice via the tail vein, and then TF-1 cells were subcutaneously inoculated in the right rib of the mice.
  • the group administration date was set as D1.
  • the administration time was D1 (1 mouse before cell inoculation), D8, and D15.
  • the administration method was intravenous injection.
  • the data were recorded by measuring the tumor volume and body weight twice a week for a total of 3 weeks.
  • the body weight, tumor volume and tumor weight of each group of animals were expressed as mean ⁇ standard error (Mean ⁇ SEM), and graphed using Graphpad Prism 9 and Excel software, and statistically analyzed using one-way analysis of variance.
  • V 1/2 ⁇ L long ⁇ L short 2
  • Relative volume (RTV) VT / V0
  • Tumor inhibition rate (%) ( CRTV - TRTV )/ CRTV (%)
  • V0 and VT are the tumor volumes at the beginning and end of the experiment, respectively.
  • CRTV and TRTV are the relative tumor volumes of the blank control group (Blank) and the experimental group at the end of the experiment, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une protéine de fusion bifonctionnelle, comprenant un premier domaine reconnaissant spécifiquement le récepteur de l'interleukine-6 (IL-6 r), et un second domaine se liant spécifiquement à la protéine de surface cellulaire CD47. L'invention concerne également un procédé d'utilisation de ladite protéine de fusion bifonctionnelle pour traiter ou prévenir des maladies associées à IL-6 R et/ou CD47.
PCT/CN2023/117865 2022-11-07 2023-09-08 Protéine de fusion bifonctionnelle et son utilisation WO2024098939A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211386080.X 2022-11-07
CN202211386080 2022-11-07

Publications (1)

Publication Number Publication Date
WO2024098939A1 true WO2024098939A1 (fr) 2024-05-16

Family

ID=91031887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/117865 WO2024098939A1 (fr) 2022-11-07 2023-09-08 Protéine de fusion bifonctionnelle et son utilisation

Country Status (1)

Country Link
WO (1) WO2024098939A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563155A (zh) * 2016-05-27 2019-04-02 北京伟德杰生物科技有限公司 抗体、包含该抗体的组合物和试剂盒及其使用方法
CN110087673A (zh) * 2016-07-19 2019-08-02 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
CN111303293A (zh) * 2018-11-14 2020-06-19 杭州尚健生物技术有限公司 一种融合蛋白及其用途
CN111905101A (zh) * 2020-07-03 2020-11-10 中山大学 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其***的方法
WO2021101966A1 (fr) * 2019-11-18 2021-05-27 The Board Of Trustees Of The Leland Stanford Junior University Traitement de la fibrose avec blocage combiné de l'il-6 et du point de contrôle immunitaire
CN112969719A (zh) * 2019-03-06 2021-06-15 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
US20220056135A1 (en) * 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109563155A (zh) * 2016-05-27 2019-04-02 北京伟德杰生物科技有限公司 抗体、包含该抗体的组合物和试剂盒及其使用方法
CN110087673A (zh) * 2016-07-19 2019-08-02 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
CN111303293A (zh) * 2018-11-14 2020-06-19 杭州尚健生物技术有限公司 一种融合蛋白及其用途
US20220056135A1 (en) * 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
CN112969719A (zh) * 2019-03-06 2021-06-15 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
WO2021101966A1 (fr) * 2019-11-18 2021-05-27 The Board Of Trustees Of The Leland Stanford Junior University Traitement de la fibrose avec blocage combiné de l'il-6 et du point de contrôle immunitaire
CN111905101A (zh) * 2020-07-03 2020-11-10 中山大学 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其***的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIE, S. ET AL.: "Biology Drives the Discovery of Bispecific Antibodies as Innovative Therapeutics", ANTIBODY THERAPEUTICS, vol. 3, no. 1, 17 February 2020 (2020-02-17), XP055776258, DOI: 10.1093/abt/tbaa003 *
XIE QI, HE HUA, WU YA‐HONG, ZOU LU‐JIE, SHE XIAO‐LING, XIA XIAO‐MENG, WU XIAN‐QING: "Eutopic endometrium from patients with endometriosis modulates the expression of CD36 and SIRP‐α in peritoneal macrophages", JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, WILEY-BLACKWELL PUBLISHING ASIA, JP, vol. 45, no. 5, 1 May 2019 (2019-05-01), JP , pages 1045 - 1057, XP093149222, ISSN: 1341-8076, DOI: 10.1111/jog.13938 *

Similar Documents

Publication Publication Date Title
WO2022042690A1 (fr) Anticorps anti-ccr8 et application correspondante
US10875926B2 (en) Fully human antibody against human CD 137
AU2018256392B2 (en) Anti-PD-L1 antibody and use thereof
US20220002412A1 (en) Humanized Anti-PD-1 Antibody and The Use Thereof
CN111269315B (zh) 针对bcma的单克隆抗体
EP4101867A1 (fr) Anticorps bispécifique anti-cd3 et anti-cd123 et son utilisation
EP4375299A1 (fr) Anticorps b7-h3 et son utilisation
WO2022194201A1 (fr) Anticorps ou fragment de liaison à l'antigène de celui-ci ciblant cldn18.2 et utilisation associée
JP2022532173A (ja) ヒト化抗ｃｄ１３７抗体およびその使用
EP4389770A1 (fr) Anticorps bispécifique et son utilisation
TW201522373A (zh) 抗ｃｄ５２之抗體
WO2023020459A1 (fr) ANTICORPS MONOCLONAL CIBLANT SIRPα ET SON UTILISATION
CN113348179A (zh) 特异性识别粒细胞-巨噬细胞集落刺激因子受体α的抗体及其用途
WO2024098939A1 (fr) Protéine de fusion bifonctionnelle et son utilisation
US20230192797A1 (en) Human il-15 mutant and uses thereof
EP4130039A1 (fr) Développement et application d'un activateur de cellules immunitaires
CN117337306A (zh) 靶向pd-l1和cd73的特异性结合蛋白
CA3208624A1 (fr) Anticorps de proteine garp et son application
CN115884989A (zh) 靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
WO2024098940A1 (fr) Anticorps bispécifique et son utilisation
WO2023030311A1 (fr) Protéine de liaison à l'antigène ciblant siglec15 et son utilisation
US20240139314A1 (en) Engineered chimeric fusion protein compositions and methods of use thereof
WO2022258011A1 (fr) Anticorps humanisé anti-pd-1 ou fragment de liaison à l'antigène de celui-ci et utilisation associée
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
WO2024120418A1 (fr) Anticorps anti-ccr8 et utilisation associée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23887633

Country of ref document: EP

Kind code of ref document: A1